31 patents currently held
5 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Oct 2032. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Oct 2032
Next term end
21
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Mar 2033 · High confidence
Also notable
Ends Mar 2033 · High confidence
Also notable
Ends Nov 2033 · Medium confidence
RNA-DIRECTED DNA CLEAVAGE BY THE Cas9-crRNA COMPLEX
US 9,637,739
The most cited patent in this portfolio, cited by 426 later US patents, top 1% of utility patents granted in 2017 in our data. Protection runs to 2033.
RNA-DIRECTED DNA CLEAVAGE BY THE Cas9-crRNA COMPLEX
US 11,555,187
Cited by 87 later US patents, top 1% of utility patents granted in 2023 in our data. Protection runs to 2033. A terminal disclaimer caps this term to an earlier patent's.
System and Method for a Biomimetic Fluid Processing
US 11,396,016
A family of 6 related applications built on the 2022 grant. Protection runs to 2033. A terminal disclaimer caps this term to an earlier patent's.
Formerly held, still cited
Notable
Ends Apr 2035 · High confidence
Cited by 50 later US patents, top 5% of utility patents granted in 2020 in our data. Protection runs to 2035.
now held by President and Fellows of Harvard College
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 2 fees due Jan 9 to 30, 2027 · next Jan 9
- 1 fee due Feb 20, 2027The maintenance fee for Programmable RNA Shredding by the Type III-A CRISPR-Cas System of Streptococcus Thermophilus (US 10,385,336) comes due Feb 20, 2027. Unpaid by Aug 20, 2027, it lapses early.
- 1 fee due Jun 26, 2027The maintenance fee for System and Method for a Biomimetic Fluid Processing (US 11,850,589) comes due Jun 26, 2027. Unpaid by Dec 27, 2027, it lapses early.
- 1 fee due Jul 2, 2027The maintenance fee for Systems and Methods for Encapsulation and Multi-Step Processing of Biological Samples (US 11,860,076) comes due Jul 2, 2027. Unpaid by Jan 3, 2028, it lapses early.
- 1 fee due Sep 17, 2027The maintenance fee for Systems and Methods for Biomimetic Fluid Processing (US 10,590,373) comes due Sep 17, 2027. Unpaid by Mar 17, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
What they patent
The 5 largest of its 21 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| System and Method for a Biomimetic Fluid Processing | 4 in force | to Nov 2033 |
| Systems and Methods for Encapsulation and Multi-Step Processing of Biological Samples | 3 in force | to Apr 2042 |
| RNA-DIRECTED DNA CLEAVAGE BY THE Cas9-crRNA COMPLEX | 3 in force | to Feb 2035 |
| Systems and Methods for Biomimetic Fluid Processing | 2 in force | to Apr 2036 |
| Programmable RNA Shredding by the Type III-A CRISPR-Cas System of Streptococcus Thermophilus | 2 in force | to Sep 2035 |
Patents held now
Soonest term end first.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,725,467 | Fluorinated Benzenesulfonamides as Inhibitors of Carbonic Anhydrase In force (reinstated) · High confidence | In force (reinstated) | High confidence | |
| US 9,347,093 | Nucleic Acid Production and Sequence Analysis In force · High confidence | In force | High confidence | |
| US 9,988,673 | Nucleic Acid Production and Sequence Analysis In force · High confidence | In force | High confidence | |
| US 9,637,739 | RNA-DIRECTED DNA CLEAVAGE BY THE Cas9-crRNA COMPLEX In force · High confidence | In force | High confidence | |
| US 10,844,378 | RNA-DIRECTED DNA CLEAVAGE BY THE Cas9-crRNA COMPLEX In force · High confidence | In force | High confidence | |
| US 11,555,187 | RNA-DIRECTED DNA CLEAVAGE BY THE Cas9-crRNA COMPLEX In force · High confidence | In force | High confidence | |
| US 10,343,163 | System and Method for a Biomimetic Fluid Processing held by Brigham and Women's Hospital, Inc., President and Fellows of Harvard College and Vilnius University In force · High confidence | In force | High confidence | |
| US 10,590,373 | Systems and Methods for Biomimetic Fluid Processing held by Brigham and Women's Hospital, Inc., President and Fellows of Harvard College and Vilnius University In force · Medium confidence | In force | Medium confidence | |
| US 10,710,073 | System and Method for Biomimetic Fluid Processing In force · Medium confidence | In force | Medium confidence | |
| US 11,396,016 | System and Method for a Biomimetic Fluid Processing In force · Medium confidence | In force | Medium confidence |
Also on record, not counted in the 31: 5 patents in force now held by others · 5 patents ended · 18 applications pending · 10 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.